Bringing Cutting Edge Technologies to Academic Researchers Through the Academic Access Program

This post was written by guest blogger Iain Ronald, Director Academic/Government Market Segment at Promega.

My back story is similar to most of you reading this blog, high school education, undergraduate degree then onto a postgraduate degree. However, over 25 years ago during my undergraduate study, I was fortunate enough to work in the lab of Professor Ray Waters studying DNA damage in S. cerevisiae as a model organism and at the time PCR was cutting-edge technology and the PCR license was in full effect. However, there was one company that was fighting the good fight to democratize PCR for the good of the scientific community, Promega.

I became enamored with Promega then, and the next steps in my career were taken with a view to working at this company who, for all intents and purposes, seemed to really care about the progression of science beyond self-aggrandizement.

Now that I am working at Promega in a position where I can bring benefit to our academic community, I have pondered what I can do to equal the disruptive attitude I observed in this company all those years ago when they were fighting the then “big tech” for the enablement of the scientific community. 

Reporter bioassays are one of hte many offerings of the academic access program.
Continue reading “Bringing Cutting Edge Technologies to Academic Researchers Through the Academic Access Program”

How Promega Helped Our Lab Scale Up Drug Discovery for Bloodborne Pathogens

This blog was written by Sebastien Smick, Research Technician in Dr. Jacquin Niles’ laboratory at Massachusetts Institute of Technology (MIT)

Our lab is heavily focused on the basic biology and drug discovery of the human bloodborne pathogen Plasmodium falciparum, which causes malaria. We use the CRISPR/Cas9 system, paired with a TetR protein fused to a native translational repressor alongside a Renilla luciferase reporter gene, to conditionally knock down genes of interest to create modified parasites. We can then test all kinds of compounds as potential drug scaffolds against these gene-edited parasites. Our most recent endeavor, one made possible by Promega, is a medium-low throughput robotic screening pipeline which compares conditionally-activated or-repressed parasites against our dose-response drug libraries in a 384-well format. This process has been developed over the past few years and is a major upgrade for our lab in terms of data production. Our researchers are working very hard to generate new modified parasites to test. Our robots and plate readers rarely get a day’s rest!

Continue reading “How Promega Helped Our Lab Scale Up Drug Discovery for Bloodborne Pathogens”

Drug Repurposing Screens: Redeploying Old Dogs for New Tricks

This blog was written by guest author, Amy Landreman, PhD.

Drug repurposing, identifying new uses for approved or investigational drugs, is an attractive strategy when looking for new disease treatments. Because the compounds have already gone through some level of pre-clinical optimization and safety testing, this approach can reduce risk, reduce cost, and speed up the timeline for further drug development. An additional benefit of this approach is that it can result in new biological insights or a better understanding of disease mechanisms since these compounds usually already have some level of mechanistic characterization. Indeed, there are now a number of compound collections openly available specifically for the purpose of facilitating drug repurposing efforts. For example, the ReFRAME (Repurposing, Focused Rescue, and Accelerated Medchem) library is a collection of 12,000 compounds developed by Scripps Research Center and has been screened to identify novel candidate therapeutics for Cryptosporidium infection (1). The Broad Institute also offers a drug repurposing hub that contains an annotated collection of over 7,000 compounds.

Drug repurposing libraries, although often smaller than novel compound small molecule libraries, are designed for implementation into high-throughput screening workflows in order to efficiently triage compounds for the desired result. Effective compound screens require assays that can be scaled to 384 or 1536-well microplate formats and implemented in batch or continuous processing workflows. The firefly luciferase reaction has been leveraged to create many assays that are well-suited to these types of high-throughput screening approaches. In particular, the generation of “Glow” assays that have stable luminescent signals and homogenous assay design is a good fit. The signal stability allows for multi-plate processing and because the reagent is added directly to cells in culture, pre-processing steps are eliminated allowing for automated workflows. Assay reagents such as the CellTiter-Glo® Cell Viability Assay and the ADP-Glo™ Kinase Assay are commonly used in screening efforts including those done with repurposing libraries.  In addition, there are several firefly luciferase reporter assay reagents such as Steady-Glo® and Bright-Glo™ Luciferase Assays that have been optimized for high-throughput detection of firefly luciferase activity making them well-suited to repurposing screens.

Continue reading “Drug Repurposing Screens: Redeploying Old Dogs for New Tricks”

The Power of Vulnerability

Today’s blog is written by Malynn Utzinger, Director of Integrative Practices, and Tim Weitzel, ESI Architect.

If we want to reignite innovation and passion, we must rehumanize work.

-Silicon Valley CEO of Several Start-ups

If we want to rehumanize work, we need to be more human in the workplace.

-Promega’s ESI Bootcamp

Vulnerability is the birthplace of intimacy, trust connection, creativity, innovation. For leaders, it is the birthplace of trusted influence. But it is not permission to overshare.

-Brené Brown

Myths of Vulnerability

It’s important that we start off by making a few things about vulnerability crystal clear:  being vulnerable is not about over-sharing, being emotional—or worse, gushy. It is not about sacrificing necessary boundaries or letting go of all discernment when speaking. Vulnerability, as we intend it, is about being real with others. It is about being clear and honest enough within yourself that you can use courage and clarity to state a need or a perspective. Quite the opposite of requiring tears or grand displays of emotion, vulnerability can be expressed with utter command of one’s emotions, so that the clarity and authenticity of the message is what remains.

Vulnerability is also knowing that you cannot know everything or do your work perfectly or even to your full satisfaction sometimes, and it is having this same understanding and acceptance for others. It is being able to speak to that honestly so that we can build sustainable bridges between ourselves and others. We call this speaking our truths–with discernment.

Finally, vulnerability is knowing that while we must give our best efforts where and whenever we can, we must also know what we can’t control.  In most cases, what we cannot control is outcomes.  Therefore, vulnerability is embracing the uncertainty in how things will go in our relationships and in our work if we risk emotional exposure.  We cannot always know how others will hear what we share, but we can learn to take that risk and speak in service to a common goal.  For example, we might decide to share that the reason we are being so obsessive or insistent on a process is because of a past failure (perceived or real) that we still carry with us.  Even though we cannot control what others will think of our story, we trust that the sharing may help them share a need of their own or to hear our own need differently, so that we can all work together.  This is true in every relationship of our lives, where we learn to share something true for the sake of allowing another human being to know us as we are. 

Continue reading “The Power of Vulnerability”

Reflections: King’s College London iGEM 2020, Renervate and Future Prospects

Today’s guest blog about the 2020 virtual iGEM Giant Jamboree is written by Abigail Conner, Co-Team Leader of iGEM King’s College London (KCL).

In October 2019, I returned to London from Boston feeling elated after an unforgettable week at the Giant Jamboree. My team, Capacity, had just won a Silver Medal. I had the privilege of presenting in front of the judges about our work. The Giant Jamboree presented me with a vision of where Synthetic Biology will take us and its potential to radically transform our society for the better. Words cannot describe the deep sense of pride I felt to be a part of this community. For the first time, I felt truly empowered as a young scientist and was hugely inspired by the brilliance of my peers. As a result, I was beyond happy to assume the role of Team Leader of KCL’s 2020 team.

Almost immediately after touching down in the United Kingdom, I began to plan our project. Throughout the recruitment process and setting up applications, Stephanie Avraamides—the Head of Human Practices in Capacity—joined me in leading the team. As Co-Team Leaders, we would establish Renervate, a team of 19 undergraduate students from various STEM backgrounds, from Nutrition to Biomedical Engineering. Although we were fortunate to have met up in person several times before March, the onset of the COVID-19 pandemic scattered us across the world. Our team members represent sixteen different countries, meaning we had to navigate a range of time zones when working virtually. Despite this, we adapted to the virtual setting and worked tirelessly to develop Renervate. Come November, we would be rewarded for our endurance and commitment. I am thrilled to say that Renervate won a Gold Medal, Best Therapeutics Project, and nominations for Best Model and Best Supporting Entrepreneurship at last year’s Virtual Giant Jamboree.

Continue reading “Reflections: King’s College London iGEM 2020, Renervate and Future Prospects”

Technical Manuals: A New Look

This blog post was cowritten by Sara Klink and Kari Kenefick.

Promega technical manuals have a new look! But never fear, our manuals still contain the protocol instructions for correctly using Promega products and include data, product and component storage information that you need to be successful at the bench. The cover art on our manuals now incorporates the use of imagery created by David Goodsell, which you can also find on our product boxes and at www.promega.com. The new cover image is being applied as we create new technical manuals or revise existing documents. Below are the old (left) and new (right) covers to compare:

Continue reading “Technical Manuals: A New Look”

Promega Biotech Ibérica Earns Recognition for Contributions to the COVID-19 Pandemic Response in Spain

Small- and medium-sized companies are critical to the Spanish economy. During 2020 the COVID-19 pandemic made business difficult for many of these companies, yet they have demonstrated strength and resourcefulness and have led the pandemic recovery in Spain in many ways. Recently, Promega Biotech Ibérica was recognized with a Madrid Community SME (small- and medium-sized business) Award along with 15 other companies. The awards were presented by Manuel Giménez, Minister of Economy, Employment and Competitiveness of the Madrid Region, Andres Navarro delegate director of La Razón, and Francisco Marhuenda, director of La Razón. As part of the award, Promega Biotech Ibérica General Manager, Gijs Jochems, was interviewed about the award and Promega’s work in the region.

Gijs Jochems, General Manager of Promega Biotech Ibérica accepts the Madrid Community SME Award.
Gijs Jochems, General Manager of Promega Biotech Ibérica accepts the Madrid Community SME Award.

According to Gijs Jochems, General Manager of Promega Biotech Ibérica, while Promega Corporation is an American multinational company, it remains privately held, which offers a great deal of flexibility to the subsidiaries to adapt to local needs. It also allows the company to place increased emphasis on employee well-being (critical during the pandemic), reinvest profits in research and development, and work to mitigate the impact of company activities on the environment. All these business practices reflect a long-term vision of sustainable business growth.

Continue reading “Promega Biotech Ibérica Earns Recognition for Contributions to the COVID-19 Pandemic Response in Spain”

Three Pillars of ESI Mastery: Part Three

A Future Vision that Shapes Today’s Behavior

Today’s blog is written by Malynn Utzinger, Director of Integrative Practices, and Tim Weitzel, ESI Architect.

In one of our earliest blogs, we shared one of our favorite parables about a stonecutter. it went as follows:

In medieval times, a traveler happens upon a stonemason and asks him, “What are you doing?” The stonemason says wearily, “I spend long, hard days cutting and laying stone.” Further down the traveler encounters a second stonemason and asks him the same question, “What are you doing?” This stonemason, more energetically, replies. “I’m building a wall. I am blessed to have work that allows me to support my family so well.” Again, walking on, the traveler encounters a third stonemason doing the same work as the previous two; yet this stonemason is beaming with life. When the traveler asks what he is doing, he spreads his arm wide and exclaims, “I am building a cathedral that will uplift countless lives for centuries to come!”

ESI Mastery Part Three

The last pillar of Emotional and Social Intelligence (ESI) Mastery that we explore in this three-part series is the importance of identifying a vision or writing a future story. This vision or story shapes how we behave so that we can live into it.

In short, stories drive our lives. However, too often, the wrong story causes us to become stuck in a version of reality that cuts us off from giving and receiving the best of ourselves and of life.

Continue reading “Three Pillars of ESI Mastery: Part Three”

Advancing Understanding of Hypoxic Gene Regulation Using Reporter Genes: Celebrating the Work of Dr. Gregg L. Semenza

This post is written by guest blogger, Amy Landreman, PhD, Sr. Product Manager at Promega Corporation.

Oxygen is necessary for animal life. It’s essential for cellular respiration and the production of energy (ATP) we require to survive. Given the need for oxygen, it isn’t surprising that our bodies have evolved ways to sense and adapt to decreased oxygen conditions (hypoxia). We can increase the production of new blood vessels by producing vascular endothelial growth factor (VEGF) or increase red blood cell (RBC) production by increasing the levels of eythropoietin (EPO), the hormone that plays a key role in the production of RBCs. But how does our body sense low oxygen, increase EPO levels, and kick our RBC production into gear? Nobel laureate Gregg L. Semenza has been honored for his contributions to our understanding of this process, and his research demonstrates the value of reporter genes and bioluminescence for studying gene regulation.

Reporter genes and bioluminescence are important tools for studying gene regulation
Continue reading “Advancing Understanding of Hypoxic Gene Regulation Using Reporter Genes: Celebrating the Work of Dr. Gregg L. Semenza”

Celebrating 30 Years of “Glo-ing” Research

This post is written by guest blogger, Amy Landreman, PhD, Sr. Product Manger at Promega Corporation.

In December of 1990, Promega first discussed the use of firefly luciferase (luc) as an emerging reporter technology in the article, Firefly Luciferase: A New Tool for Molecular Biologists. At the time, the gene coding chloramphenicol acetyltransferase (cat)  was most commonly used by researchers, but it was thought that the bioluminescent properties of firefly luciferase, extreme sensitivity and rapid simple detection, could make a significant difference in how molecular biologists tackled their research. Several months later, the first firefly luciferase reporter vectors and detection reagents became available as products, making this new technology more broadly accessible to the research community. Today firefly luciferase is no longer a “new tool”, with it and many other bioluminescent reporter technologies being standard elements of the modern research toolbox.

Continue reading “Celebrating 30 Years of “Glo-ing” Research”